Market Overview

Jazz Pharma Begins Trial of IV Administered Erwinaze

Share:
Related JAZZ
The Wall Street Research Making Waves Today
Jazz Pharma Could Be Worth Over $200 If Xyrem Adds Long-Term Value: Here's How

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled and dosed in a clinical trial of Erwinaze^® (asparaginase Erwinia chrysanthemi) administered intravenously (IV) as an alternative method of administration to treat patients with acute lymphoblastic leukemia (ALL) with hypersensitivity to E. coli-derived asparaginase therapy.

Posted-In: News FDA

 

Related Articles (JAZZ)

View Comments and Join the Discussion!

Get Benzinga's Newsletters